Skip to content

Saturday, November 23, 2024

Latest:

Compassion beyond hospital curtains and prison bars
FROM THE LABS: From bench to bedside: Osteoarthritis gene therapy developed in the lab at Baylor is in clinical trials nationwide
The dangers of vaping
Thanksgiving nutrition: enjoying holiday favorites while staying on track with your health goals
How tau becomes a ‘bad guy’ that contributes to Alzheimer’s disease

Home
Momentum
From The Labs
- About From the Labs
- Follow From The Labs on Twitter
Policywise
- About PolicyWise
- Follow @BCMEthics on Twitter
The Stitch
- About The Stitch
Progress Notes
bcm.edu

TGF-β

Targeting TGF-β for treatment of osteogenesis imperfecta

March 22, 2022 brittle bone disease, fresolimumab, osteogenesis imperfecta, Research, TGF-β, treatment

A monoclonal antibody therapy that neutralizes TGF-β produced promising results in a Phase 1 clinical trial.

From the Labs: Image of the Month

From the Labs: Aging signs.

Healthy Habits: A DOC-umentary Series

Archives

Archives

Search

©1998 - 2023 Baylor College of Medicine®
One Baylor Plaza, Houston, Texas 77030
(713) 798-4951